Best of Us Investors
Master Financial Health & Stock Forecast Report
NYSE: HIMS
Hims & Hers
Health, Inc.
Direct-to-consumer telehealth platform disrupting healthcare access. Now partnering with Novo Nordisk to sell GLP-1 obesity drugs — a potential game-changer.
HIMS surged +39.77% after hours on March 6, 2026 following reports of a Novo Nordisk partnership to sell Wegovy and other obesity drugs on the Hims platform — ending a months-long legal dispute.
Current Price (Close)
After Hours
52-Wk High
$70.43
52-Wk Low
$13.74
Market Cap
$3.59B
Beta
2.61
User Holdings
Kerry Grinkmeyer
Executive Summary
3 Clear Investor Takeaways
Is this a good stock to maximize 3-year ROI?
Yes, with significant upside potential. The Novo Nordisk partnership opens a massive GLP-1 revenue stream. With 59% revenue growth in 2025, strong subscriber base, and now direct access to branded obesity drugs, HIMS has a credible path to 100%+ ROI by January 2029 from the after-hours price of $22.
Is it the best option in its sector?
HIMS is the leading direct-to-consumer telehealth platform with unique positioning. Its closest peers (TDOC, AMWL, DOCS) lack the DTC brand power and GLP-1 distribution deal. HIMS is the best-positioned telehealth play for the obesity drug megatrend, though investors should also watch LLY and NVO for pure pharma exposure.
Buy, Sell, Hold, or Avoid?
BUY on the Novo catalyst. The after-hours price of $22 still represents significant upside to our moderate-case 2029 target of $48–55. Current holders should HOLD and consider adding on dips below $20. New investors should initiate a position with a stop-loss at $16. The 100% ROI goal from $22 requires ~$44 by Jan 2029 — achievable under moderate assumptions.
Investment Score
78 / 100
Strong BUY with catalyst momentum. The Novo partnership materially de-risks the GLP-1 revenue thesis. High short interest (44% of float) creates additional squeeze potential. Meets the 100% ROI-in-3-years target under moderate assumptions.
Quantitative Analysis
Core Financial Health
Profitability
Gross margin 73.8%, but operating margin only 2.7% — compression from GLP-1 costs
Liquidity
Current ratio 1.90, $577M cash — strong buffer for growth investments
Solvency
Debt/Equity 207% elevated, but $300M operating cash flow covers obligations
Efficiency
Revenue per employee trending up with platform scale; margins expanding YoY
Income Statement Highlights
Margin Trends
Prior: 79.5%
Prior: 5.1%
Prior: 6.2%
Prior: 11.8%
Note: Gross margin compression driven by GLP-1 drug costs (lower margin than core telehealth). EBITDA margin expanding due to operating leverage.
Stock Ownership & Short Interest
Ownership Breakdown
605 institutional holders. Major buyers include Vanguard, BlackRock, and ARK Invest.
Short Interest (Critical)
Extremely high short interest. The Novo catalyst could trigger a significant short squeeze. Short interest increased 12% month-over-month, indicating bears were caught off-guard.
Key Ratios
Trend-Focused Valuation Analysis
| Metric | Current | 3-Yr Avg | Industry | Signal |
|---|---|---|---|---|
| Trailing P/E | 31.14 | 62.66 | 22.82 | bullish |
| Forward P/E | 33.78 | 55.40 | 25.00 | neutral |
| PEG Ratio | 1.76 | 2.28 | 1.50 | neutral |
| Price/Book | 6.69 | 16.50 | 4.20 | bullish |
| Price/Sales | 1.75 | 5.50 | 3.80 | bullish |
| ROE (TTM) | 25.23% | Neg. | 15.00% | bullish |
| Debt/Equity | 207% | 180% | 80% | bearish |
| EV/EBITDA | 26.00 | 82.00 | 18.00 | neutral |
"At a trailing P/E of 31 — half its 3-year average — and a Price/Sales of 1.75 versus the industry's 3.80, HIMS is trading at a significant discount to both its own history and its peers. The 52-week decline of 54% has created a compelling entry point, especially with the Novo catalyst."
Growth & Kerry's Rule of 40
Revenue CAGR + EPS CAGR
Kerry's Rule of 40 measures the combined Revenue CAGR and EPS CAGR over three years — distinct from the traditional SaaS Rule of 40 which uses Revenue Growth + Profit Margins. Based on today's after-hours price of $22.00, HIMS scores exceptionally well on this metric.
3-Yr Revenue CAGR
0%
Projected 2025–2028
3-Yr EPS CAGR
0%
Projected 2025–2028
Kerry's Rule of 40
0
Rev CAGR (38%) + EPS CAGR (45%)
A score above 40 indicates strong combined growth. HIMS at 83 is exceptional, driven by the GLP-1 revenue expansion and operating leverage.
Revenue & Guidance Trajectory
| Year | Revenue | YoY Growth | Adj. EBITDA | Gross Margin |
|---|---|---|---|---|
| FY 2023 | $872M | +47% | $51M | 82.0% |
| FY 2024 | $1.48B | +69% | $177M | 79.5% |
| FY 2025 | $2.35B | +59% | $318M | 73.8% |
| FY 2026E Est. | $2.8B | +19% | $338M | 72.0% |
| FY 2027E Est. | $3.6B | +29% | $500M | 74.0% |
| FY 2028E Est. | $4.5B | +25% | $700M | 76.0% |
2026 guidance: $2.7B–$2.9B revenue, $300M–$375M adj. EBITDA. Novo partnership could push to high end or above.
Market Opportunity & TAM
Size, Growth, and Addressable Market
Telehealth Market
$120B
24% CAGR
U.S. telehealth market projected to reach $120B by 2030. HIMS holds ~2% market share with room to grow through platform expansion and new verticals.
GLP-1 / Obesity Drugs
$150B
35% CAGR
Global GLP-1 market projected at $150B+ by 2030. The Novo partnership gives HIMS direct access to branded Wegovy — the fastest-growing drug category globally.
Total Potential Market
$270B+
Combined
If HIMS captures 3-5% of combined telehealth + GLP-1 distribution, that implies $8B–$13.5B in revenue potential — 3-5x current levels. AI-driven personalization could accelerate share gains.
AI Opportunity
HIMS is leveraging AI for personalized treatment recommendations, automated prescription management, and predictive health analytics. Their technology-driven platform processes millions of health data points to optimize patient outcomes. AI reduces customer acquisition costs and increases lifetime value — a structural advantage over traditional telehealth competitors.
Peer Comparison
U.S. & Global Telehealth / DTC Health Peers
| Company | Mkt Cap | Rev Growth | Gross Margin | P/S | P/E | GLP-1 Access |
|---|---|---|---|---|---|---|
| HIMS | $3.6B | +59% | 73.8% | 1.75 | 31.1 | Yes |
| TDOC (Teladoc) | $2.1B | +3% | 68.2% | 0.80 | N/A | No |
| DOCS (Doximity) | $8.5B | +12% | 89.0% | 18.0 | 45.0 | No |
| AMWL (Amwell) | $0.4B | -5% | 42.0% | 1.20 | N/A | No |
| NVO (Novo Nordisk) | $380B | +26% | 85.0% | 8.50 | 28.0 | Maker |
| LLY (Eli Lilly) | $650B | +32% | 82.0% | 14.0 | 55.0 | Maker |
"HIMS is the only pure-play DTC telehealth platform with direct GLP-1 distribution rights. At 1.75x sales versus Doximity's 18x, it offers the most compelling risk/reward in the telehealth space. It has reached meaningful scale at $2.35B revenue and is the clear category leader in consumer health."
Scenario-Based Price Forecasts
Conservative / Moderate / Aggressive
Conservative
GLP-1 partnership underperforms, margin pressure continues, macro headwinds persist
Moderate (Base)
Novo deal executes well, revenue beats guidance, margins stabilize, moderate multiple expansion
Aggressive
GLP-1 blockbuster, short squeeze, multiple expansion to 40x earnings, new verticals launch
Valuation Methodology
Forecasts are derived from a blended DCF model (WACC: 11.5%, terminal growth: 3.5%) and forward P/E multiple analysis (25–40x range based on growth trajectory). The moderate case assumes P/E expansion to 30x on 2028E EPS of $1.75, yielding a $52 target. Macro alignment is favorable: Fed rate cuts support growth multiples, and the obesity drug megatrend provides a secular tailwind independent of economic cycles.
Risk Dashboard
3-Year Investment Risk Summary
Volatility & Market Sensitivity
This stock moves approximately 2.6x the market. High volatility creates both risk and opportunity — ideal for conviction-based position sizing.
Historical Loss Profile
HIMS has experienced severe drawdowns from its all-time high of $70+. However, each major catalyst has triggered rapid recoveries. The Novo deal is the most significant catalyst to date.
Risk-Adjusted Return
Returns have not adequately compensated for volatility over the past 12 months due to the drawdown. However, the Novo catalyst materially improves the forward-looking risk/reward profile.
Tactical Risk/Reward
Asymmetric setup: growth potential significantly exceeds loss potential from current levels. Position sizing: 2-4% of portfolio for moderate conviction, up to 5% for high conviction.
Projection Confidence
7/10
Confidence is moderately high. The Novo partnership is confirmed but execution details remain uncertain. GLP-1 revenue contribution timing, margin impact, and competitive response from Amazon Pharmacy and CVS Health create uncertainty bands around our projections. The high short interest adds unpredictable squeeze dynamics.
Qualitative Analysis
Business Model, Management & Competitive Landscape
Business Model Overview
Hims & Hers Health operates a direct-to-consumer telehealth platform that connects patients with licensed healthcare providers for personalized treatment plans. The company makes money through subscription-based access to treatments across sexual health, hair loss, dermatology, mental health, and now weight management. Their platform handles the entire care journey — from online consultation to prescription fulfillment and ongoing monitoring — eliminating traditional healthcare friction points. The Novo Nordisk partnership positions them as a primary distribution channel for branded GLP-1 obesity drugs, creating a high-value recurring revenue stream.
Management Quality
CEO Andrew Dudum is a co-founder with a strong track record of execution. He has guided the company from startup to $2.35B in revenue with consistent above-guidance performance. Insiders hold 6.6% of shares — moderate alignment. Recent insider transactions show mixed signals: some scheduled selling for tax purposes, but no large discretionary sales. Dudum has been a vocal advocate for consumer health access and has demonstrated adaptability — pivoting quickly to capitalize on the GLP-1 opportunity despite initial legal challenges from Novo.
Regulatory & Legal Risk
The primary regulatory risk has been the FDA's stance on compounded GLP-1 drugs. HIMS previously sold compounded semaglutide (generic Wegovy), which drew legal threats from Novo Nordisk. The new partnership resolves this dispute entirely — converting a major risk into a competitive advantage. Remaining risks include potential telehealth regulation changes, state-by-state licensing requirements, and FTC scrutiny of DTC health claims. The political environment is generally favorable for telehealth expansion.
Competitive Landscape
HIMS is the category leader in DTC telehealth. Teladoc (TDOC) is larger but focused on B2B employer health. Amazon Pharmacy is a potential disruptor but lacks the personalized care model. Ro (private) and Noom are niche competitors. The Novo partnership creates a significant moat — no other DTC platform has direct branded GLP-1 distribution rights. Brand strength is high among millennials and Gen Z, with strong social media presence and celebrity endorsements.
Macro Alignment
Interest Rates
Fed rate cuts expected in 2026 — supportive of growth stock multiples
Sector Cycle
Healthcare/telehealth in secular growth phase. Obesity drug megatrend is macro-independent.
Verdict
Macro SUPPORTS the investment
Technical Summary
Stock is deeply oversold with strong support at $13.74 (52-wk low). The after-hours gap to $22 will likely test the $25 resistance (50-day MA) on Monday.
Innovation & R&D
HIMS invests ~12% of revenue in R&D and technology. Key initiatives include AI-powered diagnostics, personalized compounding, and expansion into new health verticals (cardiovascular, metabolic health). The platform's data moat grows with each patient interaction.
Call to Action
Investor Summary & Actionable Guidance
Recommendation: BUY
Current holders (1,200 shares): HOLD and consider adding 200-400 shares on any dip below $20. Your position at 1.4% of portfolio is conservative — could increase to 3% given the catalyst.
New investors: Initiate a position at market open Monday. Expected open ~$22. Scale in over 2-3 weeks to average into volatility.
Stop-loss: Set at $16.00 (below the pre-catalyst close). This limits downside to ~27% while preserving upside of 100%+.
Buy Triggers
- + Novo partnership details confirmed with revenue-share terms
- + Q1 2026 earnings beat with GLP-1 revenue contribution
- + Short squeeze acceleration above $30
- + Analyst upgrades with price targets above $40
Sell Triggers
- - Novo partnership falls through or terms are unfavorable
- - FDA regulatory action against telehealth prescribing
- - Break below $16 stop-loss on high volume
- - Insider selling accelerates significantly
Macro Watch Points
- Fed rate decisions — cuts support growth multiples
- GLP-1 market data — Wegovy/Ozempic prescription trends
- Healthcare policy — telehealth regulation changes
Listen to the Analysis
Audio Podcast with Samantha, BUSI Stock Analyst
Samantha
BUSI Stock Analyst
HIMS Stock Analysis — March 6, 2026
Full report narrated by Samantha · ~11 minutes
"Welcome to Best of Us Investors. I'm Samantha, your host, and today we have a blockbuster report to share with you. We're diving deep into Hims and Hers Health on what might be the most important day in this company's history..."